Login / Signup
Editorial: HBeAg seroconversion is not sufficient to allow cessation of nucleos(t)ide analogue treatment in Caucasian hepatitis B patients.
Patrick Ingiliz
Peter Lemmer
Published in:
Alimentary pharmacology & therapeutics (2019)
Keyphrases
</>
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
hepatitis b virus
prognostic factors
peritoneal dialysis
patient reported outcomes
smoking cessation
replacement therapy